mRNA-1608 Herpes Vaccine - Precision Vaccinations News
WEBJul 28, 2024 · Moderna is developing mRNA-1608, a vaccine candidate against HSV-2 and HSV-1, with a Phase 1/2 clinical trial fully enrolled as of May 2024. The vaccine aims to prevent genital herpes lesions and infection, and …
Herpes Vaccine Candidates — Precision Vaccinations News
WEBSep 12, 2024 · mRNA-1608 is a Moderna Inc. vaccine in development for genital herpes caused by HSV-2. It is a phase 1 study that aims to induce antibody and cell-mediated immunity against the virus. Learn more about the clinical trial, the vaccine value profile, and other herpes vaccine candidates.
What’s the Difference Between Shingles and Chickenpox Vaccines?
WEBNov 2, 2017 · Shingrix is a new shingles vaccine that contains a lone protein from the varicella zoster virus, while Zostavax is a live, weakened virus vaccine. Shingrix offers higher and longer protection than Zostavax, especially for older adults, but may cause more pain at the injection site.
CoviShield COVID-19 Vaccine - Precision Vaccinations News
WEBMay 6, 2024 · CoviShield is a vaccine co-developed by AstraZeneca and the University of Oxford, produced by the Serum Institute of India (SII). It is one of the most widely used COVID-19 vaccines globally, with over 1.9 billion doses supplied and emergency approval in India and WHO recommendation.
QDENGA Dengue Vaccine — Precision Vaccinations News
WEBSep 10, 2024 · QDENGA is a two-dose vaccine approved in Europe and 40 other countries for preventing dengue fever and severe dengue caused by any of the four serotypes of the dengue virus. Learn about QDENGA's clinical trials, dosage, indication, side effects, availability, and WHO guidance.
U.S. Government Takes Herpes Vaccine Development Lead
WEBApr 4, 2024 · The U.S. National Institute of Allergy and Infectious Diseases issued a Notice of Special Interest to stimulate the development of new products for the prevention, diagnosis, and treatment of herpes simplex viruses. The notice supports various approaches, including novel antiviral molecules, latent …
Uromune MV140 Urinary Tract Infection (UTI) Vaccine
WEBSep 3, 2024 · Uromune MV140 is a sublingual vaccine that contains four inactivated bacteria that cause urinary tract infections (UTIs). It is approved for use by adults in some countries and has shown to reduce UTI rates, antibiotic use, and costs in clinical trials.
Multi-Country Herpes Immunotherapy Clinical Study Continues
WEBMar 5, 2024 · GSK is conducting a phase 1/2 clinical trial of its investigational vaccine candidate for Herpes Simplex Virus (HSV) in Europe, England, and the United States. The study aims to evaluate the safety, immune response, efficacy, and reactogenicity of HSV-targeted immunotherapy (HSVTI) in healthy and infected participants.
RSV Vaccines - Precision Vaccinations News
WEBJun 6, 2022 · Meissa Vaccines MV-012-968 is an investigational, live attenuated vaccine protecting against RSV. Meissa's intranasal live attenuated MV-012-968 vaccine candidate induces systemic solid mucosal IgA antibody response in RSV-naïve children. As of August 8, 2023, 100% of RSV-naïve infants and toddlers responded to two doses of …
Herpes Vaccine Candidate Advances in 2023 - Precision …
WEBJan 8, 2023 · BioNTech SE is testing BNT163, an mRNA vaccine that encodes three HSV-2 glycoproteins, for the prevention of genital lesions caused by HSV-2 and HSV-1. The study, which started in December 2022, is expected to enroll 108 healthy adult volunteers and complete in June 2025.